Coronavirus-focused investors have willingly backed bona fide development and egregious publicity stunts alike.
Clinical results this year from companies including Roche, Biogen and Sanofi should show whether new drug classes can arrest the development of Parkinson’s disease.
Tirzepatide’s clinical programme is set to double in size when a huge head-to-head outcome study gets under way. Costs will balloon too.
An analysis of the sellside’s consensus forecast changes reveals the winners and losers of 2019.
With Reva, Amaranth and Abbott out of the game, the pool of dissolving scaffold makers is shrinking.
The anti-CD19 MAb is Morphosys’s lead pipeline asset, and an imminent filing could see it approved next year.
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.
The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?